Accretion Nutraveda IPO GMP

February 1, 2026 Written By Mihir Gohel, Reviewed and Fact Checked by Harpal Parmar

Accretion Nutraveda IPO opens for subscription on January 28, 2026, and closes on January 30, 2026, raising funds through a fresh issue on BSE SME. Incorporated in 2021 and converted to public limited in 2025, the Gujarat-based healthcare CDMO manufactures Ayurvedic and nutraceutical products in forms like tablets, capsules, powders, oils, and external preparations from WHO-GMP certified facilities. Accretion Nutraveda IPO targets investors seeking exposure to India’s expanding wellness and herbal products market driven by rising health consciousness.

₹6

Latest IPO GMP

Last updated on 01 Feb 2026 13.48

₹129

IPO Offer Price

*cut off price

--

Listing Price

Listing date is 04/02/2026.

Expert Opinions

Market sentiment for Accretion Nutraveda IPO appears positive among SME healthcare investors, fueled by wellness sector momentum despite recent volatility in listings. Company strengths include WHO-GMP certified facilities producing diverse Ayurvedic nutraceuticals like tablets, capsules, and oils, with proven export execution to USA, Singapore, and Sri Lanka alongside strong domestic CDMO contracts. Risks encompass client concentration, regulatory changes in herbal claims, raw material quality variability, and short operating history since 2021 incorporation.

Valuation analysis for Accretion Nutraveda IPO and year 2025 demonstrates exceptional Return on Equity (ROE) of 81.22%, ROCE of 36.98%, and Net Asset Value (NAV) of ₹14.72, reflecting superior capital efficiency for rapid scaling. Long-term investment perspective favors high-growth wellness portfolios anticipating nutraceutical market doubling by 2030 through global health trends and e-pharmacy penetration.

Investor Considerations

Accretion Nutraveda IPO investors should note the company’s impressive growth trajectory, with FY 2025 revenue surging 208% to ₹16.06 crore and PAT expanding 218% to ₹2.61 crore, reflecting successful CDMO scaling from WHO-GMP facilities. Nutraceutical sector outlook accelerates with India’s wellness market projected to reach $18 billion by 2025, driven by preventive healthcare adoption and e-pharmacy penetration.

Valuation analysis for Accretion Nutraveda IPO in 2025 shows Price to Book Value of 8.76, PAT Margin of 16.33%, and Debt/Equity ratio of 0.72, commanding premium multiples justified by profitability momentum. Growth prospects include capacity expansion, new dosage forms, and export acceleration to USA/Singapore markets. Risk factors encompass client concentration, herbal regulatory scrutiny, and raw material sourcing volatility. Long-term investment goals capture wellness compounding effects, contrasting short-term SME liquidity and execution uncertainties.